Cited by 76Alzheimer's disease research and treatmentsCellular transport and secretionAutophagy in Disease and Therapy

PICALM Rescues Endocytic Defects Caused by the Alzheimer’s Disease Risk Factor APOE4

Open access
Narayan, Priyanka, Sienski, Grzegorz, Bonner, Julia M., Lin, Yuan-Ta, Seo, Jinsoo, Baru, Valeriya, Haque, Aftabul, Milo, Blerta +9 more·2020·Cell Reports

Abstract

The ε4 allele of apolipoprotein E (APOE4) is a genetic risk factor for many diseases, including late-onset Alzheimer's disease (AD). We investigate the cellular consequences of APOE4 in human iPSC-derived astrocytes, observing an endocytic defect in APOE4 astrocytes compared with their isogenic APOE3 counterparts. Given the evolutionarily conserved nature of endocytosis, we built a yeast model to identify genetic modifiers of the endocytic defect associated with APOE4. In yeast, only the expression of APOE4 results in dose-dependent defects in both endocytosis and growth. We discover that increasing expression of the early endocytic adaptor protein Yap1802p, a homolog of the human AD risk factor PICALM, rescues the APOE4-induced endocytic defect. In iPSC-derived human astrocytes, increasing expression of PICALM similarly reverses endocytic disruptions. Our work identifies a functional interaction between two AD genetic risk factors-APOE4 and PICALM-centered on the conserved biological process of endocytosis.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.celrep.2020.108224

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • APOE4-bound cholesterol, taken up by the cell, is released from the receptor in the late endosome or lysosome, and aggregation of APOE4 has been shown to cause endosomal congestion and dysfunction.

    “APOE4-bound cholesterol, taken up by the cell, is released from the receptor in the late endosome or lysosome, and aggregation of APOE4 has been shown to cause endosomal congestion and dysfunction (Narayan et al., 2020; Nuriel et al., 2017; Rawat et al., 2019).”

    From APOE2, E3, and E4 differentially modulate cellular homeostasis, cholesterol metabolism, and inflammatory response in isogenic iPSC-derived astrocytes (2022) · cites this paper as Narayan et al., 2020

    The Results section on iPSC-derived astrocytes reports that APOE4 disrupts early endocytosis, supporting the general claim of endocytic dysfunction. It does not describe APOE4-bound cholesterol being released from a receptor in late endosomes or lysosomes. The yeast-model Results section instead reports that APOE4 did not accumulate in protein aggregates and that the observed defects were not a response to aggregation. Page numbers were not available in our copy. (LLM, conf=0.88)

    Experimental — accuracy not yet measured
  • APOE4 iPSCs exhibit defects in endocytosis.

    “APOE4 iPSCs also exhibit defects in endocytosis (Narayan et al., 2020).”

    From APOE traffics to astrocyte lipid droplets and modulates triglyceride saturation and droplet size (2024) · cites this paper as Narayan et al., 2020

    The Results section (‘APOE4 disrupts endocytosis in iPSC-derived astrocytes’) reports reduced early endocytosis in APOE4 astrocytes compared with APOE3 astrocytes. The tested cells were derived from iPSCs; the cited passages do not establish an endocytic defect in undifferentiated APOE4 iPSCs themselves. (LLM, conf=0.87)

    Experimental — accuracy not yet measured
  • A person with one copy of the APOE ε4 allele is more likely to be affected than a person with two copies.

    “A person with one copy of this allele is more likely to be affected than a person with two copies [42,43,44].”
  • The APOE ε4 allele greatly increases AD risk.

    “The AD risk is greatly increased by the APOE ε4 allele.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Narayan, P., Sienski, G., Bonner, J. M., Lin, Y.-T., Seo, J., Baru, V., Haque, A., Milo, B., Akay, L. A., Graziosi, A., Freyzon, Y., Landgraf, D., Hesse, W. R., Valastyan, J., Barrasa, M. I., Tsai, L.-H., & Lindquist, S.
Affiliations
  • National Institutes of Health (US)
  • Whitehead Institute for Biomedical Research (US)
  • Massachusetts Institute of Technology (US)
  • Howard Hughes Medical Institute (US)
Corresponding author
Tsai, Li-Huei
Venue
Cell Reports
Publisher
Elsevier BV
Published
2020-10
Volume
33
Issue
1
Pages
108224
ISSN
2211-1247 (ISSN-L)
OpenAlex
W3092088846
Cited by
75
References
50
Citations by year
2026: 5 · 2025: 10 · 2024: 16 · 2023: 15 · 2022: 15 · 2021: 12 · 2020: 2
FWCI
6.61
Type
journal article
Language
en
Open access
Locations
  • Cell Reports (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
  • Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, cc-by-nc-nd)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc-nd)
Funders
  • Howard Hughes Medical Institute
  • American Parkinson's Disease Foundation
  • Helen Hay Whitney Foundation
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01AG058002, U54-HG008097, RF1AG062377)
  • University of California, San Francisco
  • AstraZeneca
  • EMBO (ALTF 829-2015)
  • Edward N. and Della L. Thome Memorial Foundation
  • European Molecular Biology Organization (NIA AG055697-03)
  • JPB Foundation
  • Robert A. and Renee E. Belfer Family Foundation
  • National Institutes of Health (R21 NS087557)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular transport and secretion
  • Health Sciences › Medicine › Epidemiology › Autophagy in Disease and Therapy
Keywords
PICALM, APOE ε4, Alzheimer's disease, endocytosis, astrocytes, iPSC-derived astrocytes, genetic modifiers, yeast model
MeSH terms
Alzheimer Disease, Endocytosis, Humans, Risk Factors, Apolipoprotein E4

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review